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HIV plasma viremia and CD4+ lymphocyte counts dictate the classification of HIV+ 
disease progression to Acquired Immunodeficiency Syndrome (AIDS), i.e. progressor (PR) vs. 
non-progressor (NP). In the absence of antiretroviral therapy, NP CD4+ counts remain stable and 
plasma viremia is substantially reduced. Recent data affirms that NPs exhibit decreased trans-
infection efficiency due to reduced cellular cholesterol levels in antigen presenting cells (APCs) 
through cholesterol efflux protein, ABCA-1. Because defective trans infection in NPs was also 
observed prior to seroconversion, it is believed that nonprogression is influenced by a genetic trait. 
Further transcriptome analysis of Multicenter AIDS Cohort Study (MACS) immature dendritic 
cells (iDCs) reveals elevated expression profiles for Siglec-10, CD1B, and Palladin (PALLD) in 
NPs compared to PRs. While the explicit mechanism remains elusive, our aim is to elucidate the 
genetic origin of NP viremic control. I have hypothesized that upregulated expression of Siglec-
10, CD1b, and Palladin in HIV+ MACS NPs is responsible for control of HIV progression by 
attenuating trans infection between iDCs and CD4 lymphocytes through unrelated molecular and 
immunological mechanisms. 
MACS CD14+ monocytes were cultured with IL-4 and GM-CSF to yield iDCs. Protein 
expression of Siglec-10, CD1B, and PALLD in seronegative (SN), PR, and NP iDCs has been 
assessed using flow cytometry. Quantitative PCR (qPCR) analysis of MACS iDCs RNA is used 
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for corroboration of gene expression data from the transcriptome findings. TaqMan® SNP 
genotyping assays examined if there is a link between NP disease state and single base-pair 
variations within DNA. 
Flow cytometry shows no significant difference in Siglec-10, CD1b, or PALLD protein 
expression levels between PR and NP donors. SyBr green qPCR primers for resulted in artefactual 
amplicons for control and experimental melt curves. IDT Taq-Man® primers were subsequently 
designed. Analysis of qPCR data shows significant differences in CD1b and PALLD expression 
levels between NPs and PRs (p < 0.05). Haplotype analysis of CD1b SNPs between NP, PR, and 
SN individuals via TaqMan Genotyping was not statistically significant. 
Public Health Significance: Identifying the underlying genetic factors that drive HIV-1 
disease progression could reveal potential therapeutic targets with the long term aims of improving 
HIV health outcomes. 
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1.0  INTRODUCTION 
In 1981, Acquired Immunodeficiency Syndrome (AIDS) captured the attention of the 
medical and scientific community2. Initially, it was exclusively associated with homosexual men 
with unique opportunistic infections and a rare type of endothelial cancer known as Kaposi’s 
sarcoma3. Concrete epidemiological data purported that the etiological agent was a sexually 
transmitted pathogen in which homosexuality and bisexual activity served as the greatest risk 
factor3. HIV, the causative agent of AIDS, was isolated from patients two years later4. Current 
research has established that HIV is transmitted through several definitive routes: sexual (i.e. 
between heterosexual and homosexual individuals), perinatal (i.e. mother to fetus transmission), 
and percutaneous (i.e. drug users)5. Despite modern advances in the treatment and maintenance of 
HIV through highly active antiretroviral therapy (HAART), over 2.5 million individuals 
worldwide are infected annually6. As researchers continually search for a sustainable cure, 
investigating the underlying molecular and genetic factors that drive HIV infection remains a top 
priority. 
1.1 HIV PATHOGENESIS 
 HIV’s viral life cycle has been studied extensively, elucidating entry and attachment 
factors, as well as transmission7,8. In the vast majority of infections, HIV invades host immune 
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cells through mucosal exposure (e.g. vaginal or anal mucosa in adults), and it replicates within 
helper T-cells, macrophages, and monocytes9,10. More specifically, binding of the CD4 T-cell 
receptor and CCR5/CXCR4 co-receptors via HIV gp120/41 spikes are crucial factors in cell entry 
as well as virulence, disease progression, and cell tropism7,8. 
Receptor mediated fusion of host and viral envelopes facilitates capsid entry into the host 
cytoplasm. As a single stranded RNA retrovirus, the HIV genome is converted into double 
stranded DNA via viral RNA dependent DNA polymerase, also known as reverse transcriptase. 
Viral integrase incorporates the new dsDNA into the host genome, forming an undetectable 
provirus. Host cell machinery is used to transcribe and translate the provirus in order to create 
transmissible, infectious progeny, which undergo further processing and maturation by HIV 
protease prior to budding. Hallmark indicators of HIV infection include depleted CD4+ 
lymphocyte counts and persistent, elevated levels of plasma viremia11. 
1.2 DCS FUNCTION AS IMMUNOLOGICAL SENTINELS 
DCs bridge the gap between the innate and adaptive immune response by surveying 
lymphoid tissues, blood, and various organs; broadly recognizing pathogenic features; and 
activating CD4 helper T cells through antigen presentation12,13. In order to display antigens on the 
cellular surface, microbial and viral pathogens are degraded into smaller peptide fragments and 
transported to the dendritic cell surface through highly specific mechanisms, namely through the 
Major Histocompatibility Complex (MHC) I and II pathways. 
DCs exist in different states based on expression of surface markers and cytokine profile 
production14. Immature dendritic cells are primarily responsible for maintaining immune tolerance 
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by preventing strong reactivity with host antigens. When immature dendritic cells phagocytize 
foreign pathogen encountered in peripheral tissues, they migrate to regional lymph nodes and 
subsequently undergo activation via upregulated expression of chemokine receptors, co-
stimulatory molecules, adhesion molecules, and MHC molecules15. Mature dendritic cells are 
responsible for priming and activating T-cells through antigen presentation, which allows for 
highly specific and coordinated host response against foreign pathogens. 
DC subtypes, while all originating from bone-marrow (hematopoietic), can be further 
classified into two subtypes on the basis of functionality, specialization, and phenotype: classical 
DCs (cDCs)—also known as myeloid DCs (mDCs)—and plasmacytoid DCs (pDCs)16–18. Each 
have distinct roles within the immune response. 
cDCs account for roughly one to five percent of tissue cells within the body, and they patrol 
both lymphoid and non-lymphoid tissues17. They are capable of antigen processing and 
presentation to T cells, priming naïve T cells, and exhibit upregulated HLA-DR (MHC II), CD11c, 
CD13, CD33, and CD11b expression16,19. 
In contrast, pDCs are found primarily within the bloodstream and can travel to lymphoid 
tissues17. Unlike like their classical counterparts, steady state pDCs express much lower levels of 
CD11c and HLA-DR, and they can be distinguished by their enhanced expression of CD123, 
CD303, and CD30416,17. They also have been associated with upregulating Type 1 IFN response 
upon viral infection20. Although antigen presentation is possible, priming of naïve T cells is far 
less robust in pDCs than mDCs15. 
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1.2.1 Models of DC Mediated HIV Infection: cis versus trans 
Given the diverse role of dendritic cells in immunological surveillance, it has been shown 
that HIV exploits the interaction between dendritic cells and helper T-cells, which increases T-cell 
susceptibility to infection14. Classical cis infection involves the direct entry and binding of the CD4 
receptor in target cells, fusion of host and viral envelope, productive viral replication, and 
transmission of progeny21. 
In contrast, dendritic cells form highly productive infectious synapses that target CD4 
lymphocytes through trans infection via C-type lectin receptors and the host endocytic 
pahway14,21,22. Viral gp120 binds C-type lectin receptor DC-SIGN with high affinity, which allows 
the internalization of HIV into early endosomes and DC transportation into lymphoid tissue14. It 
has been observed that the internalized virus has persisted for several days in an infectious state 
within subcellular compartments, while hiding from host surveillance—also known as the Trojan 
Horse Hypothesis14,23. Following entry into lymphoid tissue, retrograde transport of HIV shuttles 
the virus to the DC surface, which buds from the host cell and is transferred across the infectious 
synapse to infect the CD4 T-cell. Canonical lysosomal degradation of the endocytosed virus by 
host defenses is inhibited during trans infection by redirecting the virus during trafficking24. 
Although DCs are responsible for transmission of HIV to CD4 lymphocytes, they are 
drastically less susceptible to infection than T-cells. This is partially due to upregulated interferon 
responses and decreased CCR5 expression in mature DCs25. Differences in susceptibility to HIV 
infection can also be observed between DC subtypes. Myeloid dendritic cells must be infected 
with to ten to one-hundred times more HIV than iDCs.26 However, research has shown that levels 
of mDCs directly correlate with HIV disease progression rates27. That is, mDCs levels in the blood 
remained persistently low despite ART in rapid and untreated PRs, while LTNPs exhibited higher 
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numbers. Plasmacytoid DC numbers were similar to CD4+ lymphocyte counts for all donor types. 
This implies that HIV continually affects mDCs during infection despite ART and slowing of 
disease progression. 
1.3 NATURAL HISTORY OF UNTREATED HIV INFECTION 
HIV infection progresses through three stages that vary in length: acute, asymptomatic 
chronic, and symptomatic. Each stage presents distinct clinical and molecular manifestations. 
Acute or primary infection lasts roughly two to six weeks in HIV+ patients, and plasma viremia 
peaks at this stage28. Roughly fifty to eighty percent of infected individuals experience influenza-
like symptoms during the initial weeks of acute infection, including but not limited to: fever, 
myalgia, headache, rashes, and pharyngitis29. Circulating CD4 lymphocytes quickly decline to less 
than 500 cells per mm3 due to HIV’s cytopathic effects, but are eventually restored to roughly 800 
cell per mm3 as the acute infection is controlled through CTL response and antibody production 
during seroconversion28,30,31. 
After three to four months of infection, individuals enter the asymptomatic chronic stage 
in which the virus persists at low levels within the body28. The viral set point, or the amount of 
virus within the blood at the start of the asymptomatic chronic stage, is a strong indicator of disease 
progression and prognosis for HIV+ patients28,32. Clinical latency can persist anywhere from six 
months to twenty years after infection15. 
When CD4 levels fall below 500 cells per μL plasma, individuals have entered the 
symptomatic stage of HIV infection. HIV-infected helper T cells present as a foreign invader that 
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must be cleared either by CTL response or programmed cell death. Production of new CD4 
lymphocytes is severely limited at this stage of infection33. 
1.3.1 Acquired Immunodeficiency Syndrome (AIDS) 
Once an individual’s CD4 counts have fallen below 200 cells per μL, he or she is diagnosed 
with AIDS34. At this stage, opportunistic infections are highly lethal for patients due to ablation of 
immune competence. They are also at higher risk of developing secondary conditions, such as 
neurological complications through HIV-Associated Neurocognitive Disorders (HAND), 
Pneumocystis carinii pneumonia, tuberculosis, and cancer29. Unless viral replication is suppressed 
through HAART, the vast majority of individuals will develop AIDS. 
1.3.2 Antiretroviral Therapy 
According to the U.S. Department of Health and Human Services, all HIV infected 
individuals are recommended to undergo HAART regardless of CD4 counts with initial 
medication combinations of an integrase strand inhibitor (InSTI) and two non-nucleoside reverse 
transcriptase inhibitors (NNRTIs)35. Evidence suggests that initiation of HAART prior to 
seroconversion depletes the latent viral reservoir and protects circulating memory T-cells36. Strict 
adherence to HAART regimens (i.e. use of 95% or more of the prescribed drugs) is required for 
maximizing survival rates in HIV+ individuals. Non-adherence is the leading cause of HAART 
failure in patients, and it has been a primary focus of targeted inteventions37. Determinants of non-
adherence have been linked to sociodemographic and psychosocial factors ranging from age, 
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gender, education level, and employment status to degree of social support, fear of discrimination 
or stigmatization to use of traditional health remedies and access to healthcare37.  
Initially introduced in 1986 as an anticancer medication, zidovudine (AZT, retrovir) was 
the first FDA-approved medication for HIV. Nearly every stage of the HIV viral life cycle can be 
targeted through HAART via six types of drugs: (1) nucleoside reverse-transcriptase inhibitors 
(NRTIs), (2) non-nucleoside reverse-transcriptase inhibitors, (3) protease inhibitors (PIs), (4) 
integrase strand inhibitors (InSTIs), (5) co-receptor antagonists, and (6) fusion inhibitors38. Viral 
entry via gp120/41-mediated binding of host receptors can be targeted by fusion inhibitors, small 
molecule and antibody-based inhibitors, and chemokine receptor antagonists. After viral entry and 
fusion, viral RT converts the ssRNA genome into dsDNA, which can be integrated into the host 
genome via integrase. As the names suggest, NNRTIs and NRTIs target RT, while InSTIs inhibit 
integrase. PIs inhibit cleavage of viral structural and non-structural proteins in order to inhibit viral 
maturation. 
Pharmacogenetics, which focuses on the role of genetics on an individual’s drug response, 
has been invaluable in determining HAART sensitivity39. Most notably, an increased sensitivity 
to NRTI abacavir is associated with multiple allelic variants for major histocompatibility 
molecules (MHC) and immunological complement protein C4A638–40. Understanding drug 
susceptibility, delivery, and efficacy through pharmacogenetics is vital for optimizing personalized 
therapeutics and management of HIV. 
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1.4 CLASSIFICATION OF DISEASE STAGES DURING HIV INFECTION 
Clinical progression from HIV to AIDS is best predicted by assaying HIV viral levels—
also known as viral titer or load—in plasma and CD4 lymphocyte numbers11. PRs, as the name 
aptly indicates, are individuals that develop AIDS roughly two to ten years after initial infection 
and typically contain more than 10,000 copies of HIV per mL of plasma11,41. The median duration 
of developing AIDS as a PR is 8.9 years. PRs can be subdivided into three categories: rapid, 
intermediate, and late progressors. Ten to fifteen percent of PRs are an extreme phenotype of HIV 
that develop AIDS within two to three years, also referred to as rapid PRs31. Intermediate PRs 
account for the majority of HIV+ patients (seventy to eight percent), and they develop AIDS within 
six to ten years post-infection with gradual declines in CD4 counts and increases in plasma 
viremia31,41. Lastly, five percent of progressors are classified as late progressors, and they maintain 
consistent CD4 counts and viremia for nearly ten years before entering symptomatic stage of HIV 
infection31. 
In the absence of HAART, NPs can maintain low levels of viremia that generally vary from 
less than fifty to 2000 copies per mL plasma and stable CD4 counts, which range from 350 to more 
than 500 cells per mL plasma11,41. Like PRs, NPs can be further classified into three types: 
intermediate or viremic controller (VC), elite controller (EC), and long-term NP (LTNP). VCs 
contain roughly 50 to 2000 copies of virus per mL plasma41. While ECs account for less than one 
percent of HIV+ individuals, they maintain virtually undetectable viremia at less than 50 copies of 
virus per mL and more than 500 CD4 cells per mL31,41. LNTPs are classified as individuals that 
maintain low viremia levels and stable CD4 counts in the absence of HIV/AIDS-related symptoms 
for more than ten years. Due to the vague definition of LNTPs, classification of individuals can 
overlap. 
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Lastly, seronegative (SN) individuals lack specific antibodies against HIV despite 
exposure to the virus, which can range from single-event occurrences (e.g. laboratory technician) 
to continual exposure (e.g. intravenous drug user or promiscuous sexual practices)42,43. It is 
important to note that SN status can be dictated by a variety of factors, such as lifestyle choice 
(e.g. usage of Pre-Exposure Prophylaxis), minimizing (or zero) exposure to HIV, any of the 
biological and genetic factors listed for HIV resistance, or delayed seroconversion42–44. A small 
subset of SN individuals, known as highly exposed SNs, are repeatedly exposed to HIV, but do 
not contract the virus43. 
1.5 HOST GENETIC FACTORS THAT INFLUENCE HIV INFECTIVITY 
Resistance to HIV infection has been influenced by a wide variety of conditions, including 
but not limited to: host genetics, biological receptor mutations, and immunologic factors31,45,46. 
While there are a wide variety of genes that affect HIV progression (e.g. entry, cytokine receptors, 
innate and adaptive immunity), only a small fraction will be discussed in detail. When the immune 
system detects foreign antigens, a specific set of cellular surface proteins known as Human 
Leukocyte Antigen (HLA) are responsible for recognizing and presenting non-self antigen to CD4 
helper T-cells. This coordinates a highly specific immunological response against the foreign 
invader. HLA class I molecules (A-C) are expressed co-dominantly within cells, and receptor 
expression can greatly affect prognosis15. That is, HIV+ individuals that express protective 
HLA*B57 or HLA*B27 allelic variants have a better prognosis by delaying the onset of AIDS. In 
contrast, homozygosity for HLA Type I molecules, as well as expression of HLA*B37 allelic 
variant results in faster progression. 
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Another genetic host factor, CCR5-∆32 mutation, has been associated with variations in 
HIV/AIDS protection or resistance based on expression profiles. CCR5-∆32 causes a truncated 
version of CCR5, which diminishes HIV binding and fusion with host cells47. The frequency of 
the ∆32 allele is around 0.09 in Caucasian populations, while it is non-existent in Japanese and 
West African populations48,49. Homozygosity of the ∆32 mutation (approximately 1% of 
individuals) prevents HIV infection altogether by ablating CCR5 expression entirely, while 
heterozygosity (10% of individuals) delays AIDS by reducing the amount of wild type 
receptor15,47,50. 
1.6 MULTICENTER AIDS COHORT STUDY (MACS) 
The MACS is a collaborative, prospective investigation of HIV infection in homosexual 
and bisexual men established at the University of Pittsburgh Graduate School of Public Health, 
The Ohio State University Medical Center, Northwestern University Feinberg School of Medicine, 
UCLA Fielding School of Public Health, and Johns Hopkins University Bloomberg School of 
Public Health. The study aims to evaluate HIV infection in the presence and absence of HAART, 
i.e. treated and natural histories of the viral infection. Participants’ semi-annual visits to study sites 
consist of a physical examination, neurological and psychological assessment, demographic and 
health practice questionnaires, and blood draws. Since its inception in 1984, nearly 7,000 
individuals have enrolled in the MACS cohort51. 
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1.7 CELLULAR CHOLESTEROL METABOLISM LINKED TO NON-
PROGRESSOR DISEASE STATE DURING TRANS-INFECTION 
While studying MACS donors, NPs explicitly exhibited decreased metabolic cholesterol 
levels in their antigen presenting cells compared to PRs and SNs in vitro1. Moreover, NPs were 
found to have drastically less efficient dendritic cell-mediated trans infection, as well as elevated 
expression levels of ABCA1 protein, which modulates cholesterol and lipid concentrations within 
the cell. More specifically, ABCA1 is responsible for efflux of lipids and free cholesterol from the 
cell into the serum. It was hypothesized that decreased cellular cholesterol levels are disrupting the 
integrity of lipid rafts and shuttling of the virus —therefore, attenuating HIV trans infection and 
contribution to the NP state. 
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1.8 IDENTIFICATION OF TARGET GENES 
Figure 1. Heat Map of Genes Expressed Differentially between MACS PRs and NPs 
 
Total RNA was extracted from the same subset of MACS donors analyzed by Rappocciolo 
et al. in 2014. Transcript levels were assayed using Illumina’s Human HT-12 BeadChip, which 
facilitated genome-wide transcriptional coverage of candidate genes. The HT-12 assay utilizes a 
3’ in vitro translation (IVT) system, which probes the 3’ UTR trailer sequence (i.e., 
polyadenylation signal). Data was read, normalized, and transformed via Lumi software package. 
Limma software was used to generate the heat map in Figure 1. Cholesterol metabolism data 
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asserted that a genetic trait or traits were responsible for HIV nonprogression. In turn, the heat map 
generated from the same set of donors had highlighted potential genes that were contributing to 
HIV nonprogression. 
In Figure 1, gene expression levels in iDC subsets of MACS nonprogressor (denoted VC 
for viremic controller and below red horizontal header) and progressor (PR and below the blue 
horizontal header) are depicted. All genes along the vertical axis on the right exhibit highly 
significant differences in expression between donors with p < 0.0025. Note that red indicates 
decreased levels in expression, while green indicates increased levels in expression. 
Siglec-10, CD1b, and PALLD (outlined in gray) display the most visually drastic disparity 
in gene expression levels between PRs and NPs. Note that NPs (denoted as VCs) exhibit elevated 
expression levels for each target gene when compared to PRs. 
1.8.1 Siglec-10 
Siglec-10 is a human cellular surface protein that mediates protein carbohydrate 
interactions, namely by binding sialic acid residues in oligosaccharide chains. It is comprised of 
five Ig-like domains, transmembrane domain, and cytoplasmic ITIM motif52. It is broadly 
expressed in all peripheral blood leukocytes (i.e., granulocytes, monocytes, lymphocytes, and 
APCs). It is known to have at least nine unique splice variants53. 
Recent data revealed that Siglec-10 expressed in human DCs bind pseudaminic acid, a 
sugar structurally related to sialic acid, and promotes regulatory cytokine IL-10 production by 
DCs54. HIV-1 infected monocyte derived DCs have been found to produce IL-10, while Siglec-7 
(another member of the Siglec family) has been shown to bind HIV gp-120 in a sialic-acid 
mediated manner55,56. In relation to HIV pathogenesis, IL-10 has been shown to modulate viral 
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persistence by altering T-cell activity. Moreover, IL-10 promoter SNPs associated with 
upregulated IL-10 production have been linked to higher T-cells counts and protection against HIV 
progression57,58. I have hypothesized that upregulated Siglec-10 expression in NPs is indirectly 
decreasing trans infection efficiency by increasing IL-10 production in iDCs and thus stabilizing 
T-cell counts. 
1.8.2 CD1b 
CD1b is a cellular surface protein whose transmembrane glycoprotein dimerizes with β2-
microglobulin, a relatively small protein that is non-covalently bonded to the alpha subunit of the 
MHC Class 1 molecule59,60. As a member of the CD1 family of proteins, it facilitates presentation 
of self and non-self lipid antigens by scanning the endocytic pathway in order to activate specific 
T cells through the adaptive immune response60. Its expression is limited to antigen presenting 
cells, i.e., DCs, B-cells, and macrophages. 
When virions bud from the host membrane during trans infection, transport directly relies 
on cholesterol synthesis. Endocytic vesicles expressing CD1b derived from HIV+ iDCs were 
found to be nearly ten times more infectious than virions during trans infection61. HIV-1 accessory 
protein Nef has been linked to viral infectivity by enhancing cholesterol synthesis and lipid raft 
transport62. Because Nef downregulates MHC-1 molecules, there is reduced NK and CD8-
mediated targeting of HIV+ cells63. In turn, it has been well established that loss of function Nef 
mutants result in attenuated viral infection64. 
Research on homologs in the CD1 family of proteins has also shown promising results: 
CD1a, which shares the same group classification CD1b, was found to colocalize with Nef, 
suggesting that endocytosis of HIV in Nef-dependent65. Nef has also been observed to decrease 
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expression of various surface cellular markers, including CD1b65. This also contributes to 
modulation of intracellular trafficking through the endo-lysosomal system to escape degradation66. 
More importantly, LTNPs have been associated with defective Nef mutations that attenuate viral 
infectivity67. 
I have hypothesized that upregulated CD1b expression in NP is a result of an upstream 
mutant viral Nef [which ultimately decreases trans infection efficiency by decreasing lipid raft 
transport and cholesterol synthesis]. Furthermore, upregulated CD1b is indicative of increased 
activity within the endolysosomal system, which reduces viremia via increased lysosomal 
processing. 
1.8.3 Palladin (PALLD) 
PALLD is an intracellular protein that modulates the binding of monomeric and 
filamentous actin68. The actin cytoskeleton is responsible for various cellular processes such as 
motility, adhesion, and contractility. Unlike Siglec-10 and CD1b, Palladin gene has three 
transcription initiation sites, and it can undergo extensive alternative splicing69. Currently, there 
are three major isoforms of PALLD: 90-92 kDa, 140 kDa, and 200 kDa. Additional minor isoforms 
have been isolated as well, and all isoforms exhibit tissue specific preferences69. 
During HIV infection, the virus has been found to utilize actin structures at the infectious 
synapse during trans infection through membrane extensions and nanotubules70–72. Evidence has 
shown that elevated palladin protein levels correlate with increased actin-based motility73. 
Furthermore, the actin cytoskeleton serves as a physical barrier that HIV must navigate in order to 
facilitate infection74. I have hypothesized that elevated Palladin expression levels in NPs are 
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indicators of upregulated actin in iDCs. Because the virus cannot overcome the upregulated 
cortical actin cytoskeleton as efficiently, HIV transmission by NPs is reduced. 
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2.0  STATEMENT OF PROJECT 
Given current transcriptome data, we hypothesize that upregulated expression of Siglec-
10, CD1b, and Palladin in HIV+ NPs is controlling HIV progression by attenuating trans infection 
between iDCs and CD4 lymphocytes through distinct molecular and immunological mechanisms. 
While the explicit mechanism of HIV disease progression remains unclear, our goal is to elucidate 
the genetic origin of NP viremic control using MACS-derived iDCs in vitro. 
2.1 AIM #1 
Validate HT-12 RNA expression results for Siglec-10, CD1b, and PALLD using RT-
qPCR. 
2.2 AIM #2 
Phenotype Siglec-10, CD1b, and PALLD protein expression between MACS PRs and NPs 
via flow cytometry. 
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2.3 AIM #3 
Analyze and identify potential association between genetic polymorphisms and HIV 
nonprogression using TaqMan® SNP genotyping assays. 
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3.0  RESEARCH DESIGN 
3.1 MAGNETIC CELL SEPARATION 
MACS donor blood was processed by a standard centrifugation protocol that utilized sterile 
filtered polysucrose and diatriozote solution (Lymphocyte Separation Medium), then was 
aliquoted and frozen in FBS/10% DMSO. 1-mL aliquots of peripheral blood mononuclear cells 
(PBMCs) were thawed at 37°C in a water bath, re-suspended in 15-mL RP-10 media (10% FBS, 
25mM Hepes in RPMI media), and centrifuged at 1200 RPM for 10’. Pelleted PBMCs were re-
suspended again in 15-mL RP-10 and incubated for 10’ at RT before undergoing separation. 
Magnetic labeling and isolation of CD14+ cells followed MACS Miltenyi Biotec protocol using 
MACS Miltenyi Biotec CD14 Human Microbeads, MACS LS column, and Buffer A (PBS, 2.0 
mM EDTA, 0.5% BSA). Viability of CD14+ and CD14- monocytes were calculated by the 
Beckman Coulter Vi-CELL™ Cell Counter and Analyzer. 1-mL aliquots of CD14- monocytes 
(maximum 5•10-6) were frozen in Nalgene cryovials in FBS/10% DMSO in -80°C for 24 hours, 
then transferred to -140°C liquid nitrogen freezers for long-term storage. PR (N=5) and NP (N=5) 
PBMC samples that were selected to undergo magnetic cell separation and other experiments were 
the same donors studied by Rappocciolo et. al in 2014. 
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3.2 IMMATURE DENDRITIC CELL CULTURE 
CD14+ monocytes were cultured in 1-mL AIM V media per 1 million cells at 37°C. 
Monocytes were fed with 103 units/mL IL-4 and GM-CSF n Day 1 and Day 3. iDCs were harvested 
on Day 5. In order to facilitate detachment from the plate, iDCs were incubated in PBS for 20’ at 
37°C, then harvested by strongly pipetting with P1000 and P200 until all cells detached from the 
plate. iDCs were counted with a hemocytometer. iDCs reserved for qPCRs were frozen in 
FBS/10% DMSO at stored at -80°C for 24 hours, then transferred to -140°C freezers for long-term 
storage.  
3.3 RNA EXTRACTION 
RNA extraction from iDCs was conducted using Ambion by Life Technologies Pure 
Link® RNA Mini Kit and followed manufacturer’s protocol. Note that frozen iDCs were re-
suspended and incubated in RPMI media prior to manual homogenization at RT for 12,000g for 
5’. Purified RNA was eluted with 25 μL RT Nuclease-Free Water (Ambion) and stored at -80°C. 
Thermo-Scientific NanoDrop Microvolume spectrophotometer and NanoDrop 2000 was used to 
evaluate RNA purity (Table 1). 
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Table 1. RNA Sample Analysis via NanoDrop 
3.4 COMPLEMENTARY DNA (CDNA) PREPARATION 
Prior to hood usage, all materials were subjected to UV light for 15’, then treated with 
RNase ZapWipes, and rinsed with Milli-Q water. Applied Biosystems TaqMan® Reverse 
Transcriptase Kit reagents (N8080234) were thawed on ice. 50 μM random hexamers were chosen 
in lieu of oligo-dTs or gene-specific reverse primers. Optional addition of 100 mM DTT was 
omitted from the master mix and was compensated with Ambion Nuclease-Free RT water. Reagent 
amounts in Table 2 were customized for (20) 20μL reactions, i.e. 15 μL of the master mix solution 
and 5 μL template RNA were added per 0.2-mL tube. Aliquots were amplified using the Applied 
Biosystems GeneAmp PCR system 9700. cDNA preps were stored at 4°C. 
 
Table 2. Master Mix of Reverse Transcriptase Reagents for cDNA synthesis 
Disease Status Nucleic Acid A260 (Abs) A280 (Abs) 260/280 260/230
NP-1 23.9 ng/µl 0.597 0.304 1.96 0.39
NP-2 11.7 ng/µl 0.293 0.141 2.08 0.16
NP-3 54.2 ng/µl 1.355 0.64 2.12 1.15
NP-4 128.7 ng/µl 3.218 1.544 2.08 0.87
NP-5 21.9 ng/µl 0.548 0.256 2.14 0.37
PR-1 3.2 ng/µl 0.079 0.034 2.3 0.09
PR-2 31.7 ng/µl 0.792 0.369 2.15 0.23
PR-3 93.5 ng/µl 2.338 1.105 2.12 1.06
PR-4 13.6 ng/µl 0.34 0.151 2.26 0.13
PR-5 15.1 ng/µl 0.377 0.192 1.96 0.18
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3.5 QUANTITATIVE POLYMERASE CHAIN REACTION (QPCR) 
Integrated DNA Technologies PrimeTime® qPCR TaqMan probe-based assay was 
executed per manufacturer protocol. Fluorescent TaqMan probes permit concurrent quantification 
of the internal control (RNA Polymerase 2) and target gene (Siglec-10, CD1b, PALLD) within a 
desired well due to distinct fluorophores (i.e. HEX and FAM respectively). IDT PrimeTime Master 
Mix (2X) solution with reference dye, target and internal control probes (20X), and nuclease-free 
water were combined and added to Applied Biosystems MicroAmp® Fast Optical 96-Well 
Reaction Plate using Eppendorf Repeater®/Combitips Advanced® system (Table 3). Target 
cDNA was added to each well, and the plate was sealed with Applied Biosystems Optical Adhesive 
Covers (Optical Adhesive Cover Starter Kit), smoothed with a roller to ensure proper seal, and 
centrifuged briefly at 1800 RPM. The qPCR was conducted using the Applied Biosystems 
StepOne Plus Real-Time PCR system and StepOne™ Software v2.1 was used to record 
amplification and fluorescence data. Specific probe info can be found in Table 4. 
PR, NP, and SN ∆CT values were compared by means of One Way ANOVA and plotted 
in GraphPad Prism 7. ∆CT values are calculated as the difference of CT values between 
housekeeping gene (i.e., RNA Polymerase II) and gene of interest (i.e., Siglec-10, CD1b, PALLD). 
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Table 3. IDT TaqMan® qPCR Probes and Primers for qPCR 
 
Table 4. qPCR Prime Time Master Mix of Reagents 
 
Flow cytometry conditions were optimized in five SN donors before using MACS PR and 
NP samples. For samples from HIV+ participants, the 96-well plate was taped during 
centrifugation, supernatant was always aspirated, and any materials in contact with virus was 
treated with bleach and incubated under UV light overnight. Cellular compensation was used in 
lieu of beads, and staining conditions were identical to the experimental conditions. 
Aliquoting cells: After counting, re-suspended iDCs in AIM-V were transferred to 96 well 
V-bottom plates at 50,000 – 100,000 cells per well. Each target protein was stained in separate 
wells. If cells weren’t being actively stained, identical amounts of monoclonal antibody (mAb) 
wash (2% FBS, 0.01% NaN3 in HBSS) wash were added. 
Sequence Molecular Weight GC Content
Probe 5'-/5HEX/ACTGAAGCG/ZEN/AATGTCTGTGACGGAG/31ABkFQ/-3' 9.40 kDa 52.00%
Primer 1 5'-CAGTTCGGAGTCCTGAGTC-3' 5.82 kDa 57.90%
Primer 2 5'-TCGTCTCTGGGTATTTGATGC-3' 6.43 kDa 47.60%
Probe 5'-/56-FAM/AGTGGCAGT/ZEN/AGCATCTCCGCATAG/31ABkFQ/-3' 8.80 kDa 54.20%
Primer 1 5'-GCACTCGTATCCAGAATCTCC-'3 6.32 kDa 52.40%
Primer 2 5'-CAGCACGACCAGAGAACAG-3' 5.82 kDa 57.90%
Probe 5'-/56-FAM/CTCATGGGA/ZEN/TCTGATATGACCGGCG/31ABkFQ/-3' 9.12 kDa 56.00%
Primer 1 5'-ACTTTTGGGCTGATATCTTGGG-'3 6.79 kDa 45.50%
Primer 2 5'-CTTCCTTGCTCCTTTTGCTATG-'3 6.61 kDa 45.50%
Probe 5'-/56-FAM/TTTTGGCTT/ZEN/GGTGCTCTGTGACTG/31ABkFQ/-3' 8.81 kDa 50.00%
Primer 1 5'-CTGCTTTGATGTCTAGTCCCTG-3' 6.68 kDa 50.00%







Viability Stain: iDCs were stained with 5 μL of 1 μL LIVE/DEAD Aqua Viability in 500 
μL PBS for 20’ in the dark at RT, and washed with PBS and centrifuged at 2500 RPM for 5’. 
Surface Stain: 5 μL FITC Mouse Anti-Human CD1b (BD555969) or BioLegend PE Anti-
Human Siglec-10 antibody (347604) were combined separately with 5 μL mAb wash in the dark. 
5 μL of the surface stain mix were added to the target well(s). Stained wells incubated for 25’ RT 
in the dark, then subsequently washed and centrifuged at 2500 RPM for 5’. 
Permeabilization and Intracellular Stain: Cells were re-suspended and permeabilized with 
Becton-Dickson Perm Buffer II in PBS, incubated for RT at 20’, add mAb wash, and centrifuged 
at 2500 RPM for 5’. Cells were stained with 5 μL of (1:100) Abcam Anti-Palladin antibody 
(ab154827) in mAb wash and incubated for 25’ RT in the dark. After washing and centrifugation 
at 2500 RPM for 5’, cells were re-suspended with 5 μL of (1:2) BD BV-421 Goat Anti-Rabbit IgG 
(Palladin secondary antibody) in mAb wash. After 25’ incubation in the dark, cells were washed 
and centrifuged at 2500 RPM for 5’. 
Fixation of cells: 240 μL of 1% PFA were used to re-suspend each pellet. Cells were stored 
at 4°C until analysis. 
Isotype control: The negative control was used to assess inherent antibody stickiness for 
unstained cells. Cells were stained with isotype mice antibodies for FITC (CD1b) and PE (Siglec-
10). Due to the unavailability of a commercial isotype for Palladin secondary antibody, 5 μL of 
undiluted secondary Palladin antibody (BV-421) served as the isotype. 
3.5.1 Fluorescent Activated Cell Sorting (FACS) 
Flow cytometry analysis was conducted on the BD LSR FORTESSA in conjunction with 
BD FACS DIVA software. Results were further analyzed using FlowJo® v10.3. PR, NP, and SN 
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Mean Fluorescence Intensity (MFI) values were analyzed by means of One Way ANOVA in 
GraphPad Prism 7. A parametric distribution of MFI values was anticipated. All isotype control 
MFI values were subtracted from target protein MFI values to normalize data and control for 
background fluorescence. 
3.5.2 Flow Cytometry Gating Hierarchy 
All donors were analyzed under the following gating template on DIVA and FlowJo 
software with variations expected between donors (Figure 2). Figure 2 depicts fluorescence in the 
isotype control in a SN donor. Thus, fluorescence and MFI values for Siglec-10, CD1b, and 
Palladin are generally shifted to the right in NP and PR donors [for histograms displaying Siglec-
10, CD1b, and Palladin-stained cells]. Viability is assessed through Am-Cyan fluorescence. 
PALLD is assessed via Pacific Blue fluorescence, CD1b via Alexa Fluorophore 488 fluorescence, 
and Siglec-10 via PE-Yellow Green fluorescence. The singlet gate was used to eliminate any 
clumped cells from analysis that could provide artificially higher fluorescence levels, while the 
monocyte gate isolated CD14+ monocyte-derived iDCs. iDC viability was assessed as a function 
of Am/Cyan fluorescence; dead cells uptake the Aqua Live/Dead stains, fluoresce, and cause a 
shift upwards on the gate. Histograms for each target protein were gated from the live cells and 
were used to enumerate the percentage and Mean Fluorescence Intensity (MFI) of positively-
expressing cells. 
It may appear as though viable singlet cells have been omitted from the gating strategy in 
Figure 2, and thus imply that I have omitted them from MACS donors. However, analysis of these 
cells on downstream gates has revealed them to inviable granulocytes, which would not prove 




Figure 2. Representative Gating Hierarchy for PR, NP, and SN Donors 
3.6 TAQMAN® SNP GENOTYPING® ASSAY 
We developed a SNP genotyping assay to detect tagging SNPs encompassing the entire 
CD1B gene and promoter. The goal of this assay is to construct haplotypes that summarize all 
genetic variation in CD1B, and to relate this to transcript expression levels and NP/PR status. The 
assay was conducted in accordance with Applied Biosystems Custom TaqMan® SNP Genotyping 
Assays protocol and amplified in the Applied Biosystems StepOne Plus Real-Time PCR 
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thermocycler. StepOne™ Software v2.1 was used to generate Allelic Discrimination Plots for each 
CD1b SNP in relation to MACS PR, NP, and SN (1:50) genomiphi DNA. HaploView software 
was used to conduct haplotype analysis of the relationship between allelic frequencies and NP 
disease state. Seven SNPs were analyzed: rs10797007, rs16840096, rs10908647, rs11583390, 
rs2569512, rs11085748, and rs8113029. Similar assays are under development for the Siglec-10 













4.0  RESULTS 
4.1  REDUCED CD1B AND PALLD EXPRESSION IS OBSERVED IN 
PROGRESSORS WHEN COMPARED TO NONPROGRESSORS VIA QPCR 
 
Figure 4. Representative qPCR Amplification Plot 
 
Figure 3. Comparison of ∆CT Values between MACS Donors 
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Cycle threshold (CT) refers to the cycle number in which quantifiable fluorescence exceeds 
background levels, and it is inversely proportional to the level of nucleic acid in the sample. That 
is, CT values < 29 indicate abundant levels of target nucleic acid, while CT values from 30-37 and 
38-40 indicate moderate and minimal amounts of nucleic acid, respectively. CT values for the 
target gene and housekeeping gene are transformed accordingly using the ∆CT method (Figure 3). 
The ∆CT method enables relative comparison between the target gene expressed in the PR or NP 
iDC sample and housekeeping gene (RNA Polymerase II), while normalization of ∆CT values is 
ensured by consistent loading of cDNA and probe samples. A representative amplification plot for 
one PR donor for Siglec-10 illustrates consistency during triplicate cDNA sample loading, as 
indicated by the uniform amplification curves for RNA Polymerase II and Siglec-10 (Figure 4). 
Furthermore, the use of differently labeled TaqMan probes enable simultaneous 
quantitation of multiple genes in one sample, which eliminates discrepancies caused by differences 
in cell numbers during RNA extraction. Unlike SyBr green primers, TaqMan probes allow 
sequence-specific annealing and prevent non-specific amplicons. During primer extension, Taq 
polymerase cleaves the fluorophore from the molecular probe and releases it from the proximity 
of the quencher, which results in a detectable fluorescent signal. Because probes for RNA 
Polymerase II and target genes have distinct fluorophores (i.e. HEX and FAM respectively), one 
can quantify gene expression levels of RPII and candidate genes in the same sample. 
Noting that positive ∆CT values indicate increased gene expression, while negative ∆CT 
values refer to decreased gene expression. Quantitative PCR analysis revealed highly significant 
differences in ∆CT values between donors for CD1b and Palladin. More specifically, CD1b and 
PALLD gene expression levels were elevated in NPs when compared to PRs (p = 0.0168, 0.0021 
respectively). In contrast, Siglec-10 gene expression was relatively consistent between PRs and 
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NPs with the exception of one NP donor (Figure 3). When comparing ∆CT values between target 
genes, PALLD expression levels are the highest with CD1b as the intermediate and Siglec-10 
expression as the lowest. 
SN donors (N = 9) that were used to optimize qPCR conditions were omitted from ∆CT 
analysis for several reasons, namely variability of SN status, differences in cell types, and non-
significant transcriptome data. Due to the large variability in the causes of SN status, it could not 
be confidently discerned that SN was a result of lifestyle choices or immunological or biological 
factors. Because optimization of TaqMan qPCR probes used SN activated CD4 T-cells in lieu of 
iDCs, it could not be accurately compared to MACS PRs and NPs iDC expression profiles. 
Activated T-cells were used due to the length of DC culture and limited availability of PBMCs 
and thus CD14+ monocytes. Lastly, no significant differences in gene expression were observed 
when comparing transcriptome data between a separate set of SN donors and MACS PRs and NPs 
(data not shown). 
Transcriptome analysis indicated that NPs universally exhibited elevated PALLD 
expression levels when compared to PRs, while some NPs showed transcript levels similar to PRs 
for Siglec-10 and CD1b (Figure 1). The transcript profiles for each target gene showed upregulated 
expression levels for the majority of NPs compared to PRs. Quantitative PCR expression results 
for CD1b and PALLD are relatively consistent with the data generated through the heat map. 
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4.2 PROTEIN LEVELS ASSESSED BY FLOW CYTOMETRY DO NOT EXHIBIT 
SIGNIFICANT DIFFERENCES BETWEEN PROGRESSORS AND 
NONPROGRESSORS 
 
Expression of target proteins in iDCs were assayed using flow cytometry between PRs 
(N=5) and NPs (N=5) via Mean Fluorescence Intensity (MFI) values. Every donor was analyzed 
under identical SSC and FSC voltages and sample flow rate to ensure consistency. During sample 
analysis on the BD LSR Fortessa, injection of PR-1 and PR-5 iDC samples into the port was 
immediately impaired despite recent re-suspension in 1% PFA, and it subsequently resulted in a 
loss of more than 70% of the samples. MFI of target proteins could not be analyzed due to 
unreliable singlet gating. That is, rather than a uniform linear distribution of singlets, cells were 
scattered randomly throughout the gate, which is indicative of blockage. Once a proper singlet 
distribution was observed after repeated attempts, there were too few recorded events in order to 
yield reliable MFI data for Siglec-10, CD1b, and PALLD (Figure 6). As a result, PR-1 and PR-5 
 
Figure 5. Comparison of Target Protein Expression via MFI between MACS Donors 
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were removed from the one way ANOVA comparison of MFI values between the three donor 
groups (Table 5, Figure 6). 
It is plausible that clumping during flow cytometry analysis of PR-1 and PR-5 was caused 
by an excess of undifferentiated and/or unviable CD14+ monocytes that were incidentally 
harvested from the DC culture. Given the diminished viability of CD14+ monocytes PR-1 (< 70%) 
after magnetic separation from donor PBMCs, it is logical that there would not be a high yield of 
viable iDCs (Table 5). In regard to PR-5, I also suspect that undifferentiated CD14+ monocytes 
were causing clumping during iDC flow analysis. It is important to note that iDCs were not assayed 
for classic molecular markers (e.g. CD86, CD80, and HLA-DR). Cell cultures were observed at 
Days 1, 3, and 5 for distinct morphological changes—indicative of iDC differentiation (data not 
shown). 
Prior to CD14+ magnetic separation due to excessive cellular clumping, PR-1 and PR-5 
PBMCs had to be treated with 40 μL of bovine pancreas DNAse. Despite nuclease treatment, 
persistent PBMC clumps from PR-1 and PR-5 had to be discarded because they would have 
significantly impeded column flow during separation. 
 There was no observed difference in protein expression levels between PRs and NPs, but 
PALLD SN donors were found to have statistically significant increased protein expression levels 
compared to NPs. 
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Table 5. MACS CD14+ and iDC Cell Count and Viability 
Figure 6. Isotype Control Singlet Gating in PR-1 and PR-5 
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4.3 CD1B SNP GENOTYPING REVEALS NO SIGNIFICANT TRENDS IN 
HAPLOTYPE ANALYSIS 
All seven CD1b SNPs were analyzed in relation to a larger pool of MACS PR, NP, and SN 
DNA beyond the PR and NPs included in the qPCR and flow cytometry analysis. Haplotype 
analysis was conducted to investigate if there was a relationship between the frequencies of alleles 
at various loci for a target SNP within the CD1b gene. No significant differences were found. 
4.4 MACS NONPROGRESSOR AND PROGRESSOR SAMPLES DISPLAY 
CHARACTERISTIC CD4 LYMPHOCYTE COUNTS AND PLASMA VIREMIA 
NP and PR donors were assayed for CD4+ T-cell counts, HIV viremia, and HLA and CCR5 
allelic variants prior to this thesis work. This figure was adapted with permission from Rappocciolo 
et al. mBio publication from 2014. Samples had been collected during bi-annual MACS visits. 
None of the donors exhibited homozygosity for HLA-57 or 27, nor did they exhibit homo- or 
heterozygosity for CCR5-∆32 variants. 
Table 6. Immunological, Virological, and Genotypic Profiles of MACS Samples 
SUBJECT Duration of Infection pre-HAART Mean CD4+ T cells per μL Mean HIV RNA copies per mL plasma HLA Genotype CCR5-Δ32
PR-1 > 5 350 ± 57 147,660 ± 65,974 38:01/49:01 WT/WT
PR-2 6.1 374 ± 28 117,151 ± 28,059 08:01/35:01 WT/WT
PR-3 6.5 204 ± 30 429,049 ± 91,578 08:01/35:03 WT/WT
PR-4 2.1 232 ± 49 396,572 ± 136,552 50:01/57:01 WT/WT
PR-5 2.9 308 ± 51 63,159 ± 36,958 37:01/06:02 WT/WT
NP-1 > 25 1,259 ± 62 4,764 ± 4,432 14:02/47:01 WT/WT
NP-2 > 8 622 ± 29 67,006 ± 26,528 35:01/41:02 WT/WT
NP-3 > 10 1,007  31 571 ± 90 15:01/42:01 WT/WT
NP-4 19.5 759 ± 57 20,893 ± 7,585 15:01/44:02 WT/WT
NP-5 > 12 541 ± 31 1,014 ± 132 15:10/42:01 WT/WT
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5.0  DISCUSSION 
Advances in the treatment of HIV via antiretroviral therapy have increased survival rates 
by preventing progression to AIDS and improved overall quality of life for HIV+ individuals. In 
a unique subset of HIV+ individuals known as nonprogressors, these participants can innately 
maintain relatively stable CD4+ lymphocyte numbers and low levels of virus without the use of 
antiretroviral drugs. Previous data showed diminished rates of HIV infection in CD4 lymphocytes 
by iDCs during trans infection within HIV NPs. By identifying the molecular and genetic origins 
of viremic control by HIV+ NPs, there could be strong therapeutic applications. 
5.1 TRANSCRIPTOME ANALYSIS REVEALS SIGNIFICANT GENE EXPRESSION 
TRENDS IN MACS NONPROGRESSORS THAT EXHIBIT DECREASED CELLULAR 
CHOLESTEROL LEVELS 
When Rappocciolo et. al discerned that HIV nonprogression during trans infection is 
associated with lower levels of cellular cholesterol in APCs, they noted that none of the NP donors 
were homozygous for CCR5-∆32 mutation or homozygous for HLA-B57 subtype. Noting that 
both mutations confer protection against HIV infection. Moreover, decreased trans infection 
efficiency was observed prior to antibody seroconversion. This implies the possibility of a novel 
genetic trait that drives HIV nonprogression. Transcriptome data using Illumina’s HT-12 assay 
was generated on the same set of donors, and it revealed highly significant different gene 
expression profiles between NPs and PRs with p < 0.0025. Siglec-10, CD1b, and Palladin gene 
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and expression levels were observed to be differentially expressed between MACS NP and PR 
donors. 
5.1.1 The functions of Siglec-10, CD1b, and Palladin expression are not interdependent 
during HIV infection 
With the transcriptome data in mind, it was hypothesized that elevated Siglec-10, CD1b, 
and Palladin in HIV+ nonprogressors were contributing to decreased trans infection efficiency in 
NPs through independent immunological and molecular mechanisms. The purpose of this thesis 
was to provide preliminary data for the continued investigation of the molecular hypotheses for 
the target genes. Considering the functionality of each protein paired with recent observations, 
there is somewhat limited evidence within current literature to link these genes to viremic control 
via cholesterol metabolism, nor is there evidence of an interconnected relationship between Siglec-
10, CD1b, and PALLD. 
Siglec-10 functions as a mediator of oligosaccharide binding within cells. Its expression is 
limited within humans, and it can be found on the cellular surface within blood leukocytes. More 
specifically, increased Siglec-10 expression in NPs is potentially lessening trans infection 
efficiency by enhancing IL-10 production in iDCs and resultantly stabilizing T-cell counts. 
 CD1b is a cellular surface protein that is responsible for lipid antigen presentation through 
the endosomal pathway. During HIV infection, Nef has been linked to CD1b expression, 
endosomal trafficking of the virus, and NP state. It was hypothesized that elevated CD1b 
expression in NP is due to an upstream mutant Nef. While it is likely that Nef ultimately decreases 
trans infection efficiency by modulating cholesterol synthesis, upregulated CD1b potentially 
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correlates to increased activity within the endolysosomal system. This increased activity 
subsequently reduces viremia through lysosomal degradation. 
However, given the role of the Palladin with actin cytoskeleton remodeling, there is the 
strongest potential for understanding HIV disease progression—specifically regarding viral 
trafficking and transmission. During HIV infection, it has been established that the cytoskeleton is 
remodeled in order to initiate viral and host envelope fusion70,71. More specifically, HIV has been 
found to exploit actin structures at the infectious synapse between antigen presenting cells and T 
cells during trans infection via membrane extensions and nanotubules68,69,72. It was hypothesized 
that Palladin is a molecular biomarker of upregulated actin production within iDCs during HIV 
infection, which results in alterations within the cytoskeleton. Because the virus cannot overcome 
the upregulated cortical actin cytoskeleton as efficiently, HIV transmission in NPs is reduced. 
5.2 QUANTITATIVE PCR RESULTS YIELD SIGNIFICANT TRENDS, WHILE 
FLOW CYTOMETRY RESULTS PROVE CONTRADICTORY 
 Two of the primary aims were to analyze RNA expression data using qPCR and phenotype 
protein levels in the same subset of MACS NP and PR donors that were analyzed in the cholesterol 
metabolism investigation. It is important to emphasize that transcript levels do not necessarily 
equate to protein expression levels. PCR and protein analysis offers a deeper insight towards the 
relationship between the three target genes and HIV NP disease status. 
Quantitative PCR results establish that there is a highly significant discrepancy in CD1b 
and Palladin gene expression levels between PRs and NPs (Figure 3). More specifically, NPs were 
found to have elevated gene expression when compared to PRs for CD1b and Palladin. When 
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compared exclusively to CD1b and PALLD transcript expression patterns from the HT-12 assay, 
there are similar trends. However, there is no statistically significant relationship observed for 
Siglec-10 between PRs and NPs. 
Although RNA levels of Siglec-10 were relatively consistent between the two donor 
populations, there are several key factors to keep in mind. Twenty percent of nonprogressors were 
found to have decreased gene expression that were similar to progressors (Figure 1). It is also 
plausible that despite ideal A260/A280 ratios at around 2.1 for RNA, the inferred contamination 
of organic molecules (e.g. residual phenols) based on the low A260/A230 ratios could have 
affected cDNA synthesis. Thereby, potentially distorting Siglec-10 gene expression levels. More 
importantly, the Illumina HT-12 data utilizes a 3’ IVT sequence. As a result, the assay does not 
detect any alternative splice isoforms that would be upstream of the poly-A tail. Because Siglec-
10 has nine unique isoforms, there is a potential explanation for the contrasting transcriptome and 
qPCR data. That is, transcriptome data could potentially fail to detect alternative isoforms of 
Siglec-10 and Palladin, which would result in artificial transcript trends. 
5.2.1 Flow cytometry analysis reveals unexpected trends 
 Protein expression of all target genes via flow cytometry staining did not equate with RNA 
transcript data from qPCR. More specifically, protein expression levels are relatively similar 
between NPs and PRs for all target genes—despite observation of significant trends in ∆CT values. 
It is important, however, to emphasize that assessment of flow cytometry staining for Siglec-10, 
CD1b, and Palladin is based on antibodies that bind surface and intracellular protein respectively. 
More specifically, monoclonal flow cytometry antibodies cannot necessarily recognize the same 
epitope expressed by protein isoforms due to extensive splicing like PALLD and Siglec-1068. 
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Abcam anti-Palladin primary antibody that was utilized does not specify its ability to recognize 
multiple isoforms. The manufacturer had predicted it only could detect a band around 131kDa. 
Because of the antibody detection limitations, there could be an artificially lower amount of 
Palladin protein detected due to the presence of multiple isoforms. As a result, assessment of 
proteins by flow cytometry is limited by the antibody binding to the protein, which may not 
necessarily reflect total protein content. In a similar fashion, the antibody utilized for detection of 
Siglec-10 is not capable of recognizing all isoform variants and subsequent epitope variants. 
 Evaluation of total protein via western blot was the next step in protein analysis. Western 
blot analysis facilitates comparison of relative protein expression per target gene in relation to total 
protein content. Lysing of iDCs during WB would ensure that all available protein for Siglec-10, 
CD1b, and PALLD would be stained—not just surface or intracellular expression detected via 
flow cytometry. Due to the limited amounts of dendritic cells after conducting flow cytometry 
from cell compensation, all remaining cells had to be used for qPCR analysis  
5.3 SNP GENOTYPING DOES NOT REVEAL POTENTIAL GENETIC LINKS TO 
HIV NONPROGRESSION 
While the third aim was unrelated to protein and transcript analysis, it was pursued to 
investigate plausible genetic links to HIV nonprogression. More specifically, TaqMan SNP 
genotyping of CD1b was conducted to evaluate the possibility that SNPs could alter the 
bioavailability of the transcript, functionality of a protein, or association with NP disease state. 
Depending on the type of SNP, there could be a wide variety of effects on the regulation or splicing 
of genes, coding sequence and thus function of a protein product, or alterations to the ORF. Seven 
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CD1b SNPs that spanned across the entire gene had been evaluated in relation to a larger set of 
MACS PRs, NPs, and SNs genomic DNA. Haplotype analysis did not reveal any significant 
differences in allelic frequency data. Although results within this system did not reveal statistically 
significant relationships,  
Palladin was omitted from SNP genotyping due to the extensive size of the gene (431,394 
bp), multiple transcription initiation sites, and extensive splicing activity. Siglec-10 genotyping 
has been delayed until the availability of RNAseq data from an ongoing project. 
5.4 EXPERIMENTAL LIMITATIONS OF IN VITRO SYSTEM 
Although in vitro monocyte derived DCs share many functions with in vivo DCs—such as 
cross presentation to CD8 T cells, activation of CD4 T cells, and production of important cytokines 
like TNF-a and IL-1, 6, and 23, the majority of in vivo primary DCs are likely not derived from 
monocytes16. This in vitro monocyte-derived DC system only provides a conceptual framework 
for HIV trans infection. Furthermore, iDCs are not representative of all DCs within the human 
body. Susceptibility of iDCs to HIV infection is distinctly different from other DC subtypes, 
namely pDCs and mDCs. As a result, this system cannot be generalized across all DCs. 
5.5 CONCLUSION AND FUTURE DIRECTIONS 
Investigating the underlying mechanisms of HIV disease progression has a strong potential 
for therapeutic applications. Evaluation of Siglec-10, CD1b, and Palladin has provided a 
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foundation for future investigations of the molecular and immunological mechanism of 
nonprogression. Future directions include analysis of total protein between NPs and PRs via 
western blot, Siglec-10 SNP Genotyping, and further analysis into Palladin’s role in actin 
remodeling and HIV disease progression. 
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6.0  PUBLIC HEALTH SIGNIFICANCE 
Identifying the underlying genetic factors that drive HIV-1 disease progression could 
reveal potential therapeutic targets with the long term aims of improving HIV health outcomes. 
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